{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:42:12Z","timestamp":1776692532761,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,13]]},"DOI":"10.7759\/cureus.58175","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T10:23:52Z","timestamp":1713003832000},"source":"Crossref","is-referenced-by-count":3,"title":["Effect of Mirabegron in Men With Overactive Bladder and Erectile Dysfunction: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Rana P","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(01)63299-3","article-title":"Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes","volume":"159","author":"Ballard SA","year":"1998","unstructured":"Ballard SA, Gingell CJ, Tang KI, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998, 159:2164-71. 10.1016\/s0022-5347(01)63299-3","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12671","article-title":"Efficacy and tolerability of sildenafil\/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction","volume":"8","author":"El-Wakeel LM","year":"2020","unstructured":"El-Wakeel LM, Fouad FA, Saleem MD, Saber-Khalaf M. Efficacy and tolerability of sildenafil\/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction. Andrology. 2020, 8:143-7. 10.1111\/andr.12671","journal-title":"Andrology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2019.02.006","article-title":"Erectile dysfunction","volume":"46","author":"Irwin GM","year":"2019","unstructured":"Irwin GM. Erectile dysfunction. Prim Care. 2019, 46:249-55. 10.1016\/j.pop.2019.02.006","journal-title":"Prim Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin JD","year":"2004","unstructured":"Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004, 16:S4-S7. 10.1038\/sj.ijir.3901205","journal-title":"Int J Impot Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2016.02.166","article-title":"Efficacy and safety of sildenafil by age in men with erectile dysfunction","volume":"13","author":"Goldstein I","year":"2016","unstructured":"Goldstein I, Tseng LJ, Creanga D, Stecher V, Kaminetsky JC. Efficacy and safety of sildenafil by age in men with erectile dysfunction. J Sex Med. 2016, 13:852-9. 10.1016\/j.jsxm.2016.02.166","journal-title":"J Sex Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0931347100","article-title":"Involvement of beta 3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in human corpus cavernosum function","volume":"100","author":"Cirino G","year":"2003","unstructured":"Cirino G, Sorrentino R, di Villa Bianca RE, et al.. Involvement of beta 3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A. 2003, 100:5531-6. 10.1073\/pnas.0931347100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4321\/s0004-06142010000800004","article-title":"Bases moleculares de la erecci\u00f3n","volume":"63","author":"Mas M","year":"2010","unstructured":"Mas M. Bases moleculares de la erecci\u00f3n. Arch Espa\u00f1oles Urol. 2010, 63:589-98. 10.4321\/s0004-06142010000800004","journal-title":"Arch Espa\u00f1oles Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.07.025","article-title":"\u03b2(3) adrenergic receptor activation relaxes human corpus cavernosum and penile artery through a hydrogen sulfide\/cGMP-dependent mechanism","volume":"124","author":"Mitidieri E","year":"2017","unstructured":"Mitidieri E, Tramontano T, Gurgone D, et al.. \u03b2(3) adrenergic receptor activation relaxes human corpus cavernosum and penile artery through a hydrogen sulfide\/cGMP-dependent mechanism. Pharmacol Res. 2017, 124:100-4. 10.1016\/j.phrs.2017.07.025","journal-title":"Pharmacol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22373","article-title":"A proof-of-concept study: mirabegron, a new therapy for overactive bladder","volume":"32","author":"Chapple CR","year":"2013","unstructured":"Chapple CR, Amarenco G, L\u00f3pez Aramburu MA, et al.. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013, 32:1116-22. 10.1002\/nau.22373","journal-title":"Neurourol Urodyn"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S372597","article-title":"Mirabegron in the management of overactive bladder syndrome","volume":"14","author":"O'Kane M","year":"2022","unstructured":"O'Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the management of overactive bladder syndrome. Int J Womens Health. 2022, 14:1337-50. 10.2147\/IJWH.S372597","journal-title":"Int J Womens Health"},{"key":"ref11","article-title":"Mirabegron for overactive bladder: a novel, first-in-class \u03b23-agonist therapy","volume":"10","author":"Imran M","year":"2013","unstructured":"Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel, first-in-class \u03b23-agonist therapy. Urol J. 2013, 10:935-40.","journal-title":"Urol J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212457114","article-title":"Mirabegron: a review of recent data and its prospects in the management of overactive bladder","volume":"4","author":"Sacco E","year":"2012","unstructured":"Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012, 4:315-24. 10.1177\/1756287212457114","journal-title":"Ther Adv Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01000.x","article-title":"Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men","volume":"5","author":"Irwin DE","year":"2008","unstructured":"Irwin DE, Milsom I, Reilly K, et al.. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008, 5:2904-10. 10.1111\/j.1743-6109.2008.01000.x","journal-title":"J Sex Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/13685538.2015.1103219","article-title":"Are urge incontinence and aging risk factors of erectile dysfunction in patients with male lower urinary tract symptoms?","volume":"19","author":"Amano T","year":"2016","unstructured":"Amano T, Earle C, Imao T, Takemae K. Are urge incontinence and aging risk factors of erectile dysfunction in patients with male lower urinary tract symptoms?. Aging Male. 2016, 19:54-7. 10.3109\/13685538.2015.1103219","journal-title":"Aging Male"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172447","article-title":"Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response","volume":"858","author":"de Oliveira MG","year":"2019","unstructured":"de Oliveira MG, Rojas-Moscoso JA, Bertollotto GM, et al.. Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response. Eur J Pharmacol. 2019, 858:172447. 10.1016\/j.ejphar.2019.172447","journal-title":"Eur J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000208","article-title":"Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms","volume":"83","author":"Wu TH","year":"2020","unstructured":"Wu TH, Shen YC, Lee WC, Wang HJ, Chuang YC. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. J Chin Med Assoc. 2020, 83:55-9. 10.1097\/JCMA.0000000000000208","journal-title":"J Chin Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen RC","year":"1997","unstructured":"Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997, 49:822-30. 10.1016\/s0090-4295(97)00238-0","journal-title":"Urology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1023\/a:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne K","year":"2002","unstructured":"Coyne K, Revicki D, Hunt T, et al.. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002, 11:563-74. 10.1023\/a:1016370925601","journal-title":"Qual Life Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900859","article-title":"The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction","volume":"14","author":"Rhoden EL","year":"2002","unstructured":"Rhoden EL, Tel\u00f6ken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002, 14:245-50. 10.1038\/sj.ijir.3900859","journal-title":"Int J Impot Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.053","article-title":"Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale","volume":"60","author":"Rosen RC","year":"2011","unstructured":"Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011, 60:1010-6. 10.1016\/j.eururo.2011.07.053","journal-title":"Eur Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01554.x","article-title":"Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors","volume":"7","author":"Althof SE","year":"2010","unstructured":"Althof SE, Buvat J, Gutkin SW, Belger M, Stothard DR, Fugl-Meyer AR. Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. J Sex Med. 2010, 7:203-15. 10.1111\/j.1743-6109.2009.01554.x","journal-title":"J Sex Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks ED","year":"2018","unstructured":"Deeks ED. Mirabegron: a review in overactive bladder syndrome. Drugs. 2018, 78:833-44. 10.1007\/s40265-018-0924-4","journal-title":"Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple CR","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014, 33:17-30. 10.1002\/nau.22505","journal-title":"Neurourol Urodyn"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2014.823","article-title":"Mirabegron: a beta-3 agonist for overactive bladder","volume":"29","author":"Bragg R","year":"2014","unstructured":"Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a beta-3 agonist for overactive bladder. Consult Pharm. 2014, 29:823-37. 10.4140\/TCP.n.2014.823","journal-title":"Consult Pharm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018802","article-title":"The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis","volume":"99","author":"Su S","year":"2020","unstructured":"Su S, Lin J, Liang L, Liu L, Chen Z, Gao Y. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis. Medicine (Baltimore). 2020, 99:e18802. 10.1097\/MD.0000000000018802","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/242334-effect-of-mirabegron-in-men-with-overactive-bladder-and-erectile-dysfunction-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T10:23:57Z","timestamp":1713003837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/242334-effect-of-mirabegron-in-men-with-overactive-bladder-and-erectile-dysfunction-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.58175","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,13]]}}}